Contract researcher Charles River Laboratories International Inc (NYSE: CRL) will dole out $292.5 million for gene therapy CDMO Vigene Biosciences with the possibility for an additional $57.5 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback